Cargando…

Systemic Chemotherapy for Advanced Hepatocellular Carcinoma: Past, Present, and Future

Systemic chemotherapy is one of the most important treatment modalities for advanced hepatocellular carcinoma (HCC). Before the introduction of sorafenib, cytotoxic agents, hormonal therapies, or many combinations of these were the mainly used modalities for systemic chemotherapy of advanced HCC. Ho...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ikeda, Masafumi, Mitsunaga, Shuichi, Ohno, Izumi, Hashimoto, Yusuke, Takahashi, Hideaki, Watanabe, Kazuo, Umemoto, Kumiko, Okusaka, Takuji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5548259/ https://www.ncbi.nlm.nih.gov/pubmed/28943630 http://dx.doi.org/10.3390/diseases3040360

Ejemplares similares

Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy
por: Suzuki, Yuko, et al.
Publicado: (2018)

EUS-guided n-butyl-2-cyanoacrylate injection therapy for ruptured isolated left gastric artery pseudoaneurysm
por: Hashimoto, Yusuke, et al.
Publicado: (2019)

Endoscopic Ultrasound-Guided Gallbladder Drainage for Aberrant Right Posterior Duct Obstruction Developing after Placement of a Covered Self-Expandable Metallic Stent in a Patient with Distal Biliary Obstruction
por: Suzuki, Yuko, et al.
Publicado: (2018)

Germline mutations in cancer-predisposition genes in patients with biliary tract cancer
por: Terashima, Takeshi, et al.
Publicado: (2019)

Immunotherapy for hepatocellular carcinoma: current status and future perspectives
por: Okusaka, Takuji, et al.
Publicado: (2018)

Transarterial infusion chemotherapy with cisplatin plus S-1 for hepatocellular carcinoma treatment: a phase I trial
por: Terazawa, Tetsuji, et al.
Publicado: (2014)

Early Relapse of Unresectable Gallbladder Cancer after Discontinuation of Gemcitabine Monotherapy Administered for 5 Years in a Patient Who Had Complete Response to the Treatment
por: Suyama, Koichi, et al.
Publicado: (2013)

Impact of the Duration of Diabetes Mellitus on the Outcome of Metastatic Pancreatic Cancer Treated with Gemcitabine: A Retrospective Study
por: Iizumi, Sakura, et al.
Publicado: (2019)

The “histological replacement growth pattern” represents aggressive invasive behavior in liver metastasis from pancreatic cancer
por: Watanabe, Kazuo, et al.
Publicado: (2020)

Phase I study of nintedanib in Japanese patients with advanced hepatocellular carcinoma and liver impairment
por: Okusaka, Takuji, et al.
Publicado: (2016)

Incidence of and risk factors for severe neutropenia during treatment with the modified FOLFIRINOX therapy in patients with advanced pancreatic cancer
por: Irisawa, Ai, et al.
Publicado: (2022)

Japanese phase I study of GC33, a humanized antibody against glypican-3 for advanced hepatocellular carcinoma
por: Ikeda, Masafumi, et al.
Publicado: (2014)

Phase I study of combination chemotherapy using sorafenib and transcatheter arterial infusion with cisplatin for advanced hepatocellular carcinoma
por: Hagihara, Atsushi, et al.
Publicado: (2014)

Impact of Endoscopic Ultrasound-Guided Tissue Acquisition on Decision-Making in Precision Medicine for Pancreatic Cancer: Beyond Diagnosis
por: Imaoka, Hiroshi, et al.
Publicado: (2021)

Case Report: Atezolizumab plus bevacizumab for combined hepatocellular-cholangiocarcinoma
por: Satake, Tomoyuki, et al.
Publicado: (2023)

Erratum to: Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics
por: Sunakawa, Yu, et al.
Publicado: (2013)

Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics
por: Sunakawa, Yu, et al.
Publicado: (2013)

Phase I trial of GBS‐01 for advanced pancreatic cancer refractory to gemcitabine
por: Ikeda, Masafumi, et al.
Publicado: (2016)

Phase I study on the safety, pharmacokinetic profile, and efficacy of the combination of TSU-68, an oral antiangiogenic agent, and S-1 in patients with advanced hepatocellular carcinoma
por: Ikeda, Masafumi, et al.
Publicado: (2014)

Current status of medical treatment for gastroenteropancreatic neuroendocrine neoplasms and future perspectives
por: Hijioka, Susumu, et al.
Publicado: (2021)

Hepatitis B Virus Reactivation during Treatment with Multi-Tyrosine Kinase Inhibitor for Hepatocellular Carcinoma
por: Shiba, Satoshi, et al.
Publicado: (2012)

A phase II study of FOLFIRINOX with primary prophylactic pegfilgrastim for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer
por: Sasaki, Mitsuhito, et al.
Publicado: (2021)

Ambulatory chemotherapy: Past, present, and future
por: Sabbagh Dit Hawasli, Racha, et al.
Publicado: (2021)

Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice: a subgroup analysis of GIDEON
por: Kudo, Masatoshi, et al.
Publicado: (2016)

Phase II study of FOLFIRINOX for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer
por: Okusaka, Takuji, et al.
Publicado: (2014)

Neoadjuvant Chemotherapy for Breast Cancer: Past, Present, and Future
por: Asaoka, Mariko, et al.
Publicado: (2020)

Liver Transplantation for Hepatocellular Carcinoma: Past, Present and Future
por: Saidi, Reza F., et al.
Publicado: (2013)

Systemic treatment of hepatocellular carcinoma: Past, present and future
por: Cidon, Esther Una
Publicado: (2017)

Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma
por: Ikeda, Kenji, et al.
Publicado: (2016)

Arsenic in medicine: past, present and future
por: Paul, Ngozi P., et al.
Publicado: (2022)

Astaxanthin: Past, Present, and Future
por: Nishida, Yasuhiro, et al.
Publicado: (2023)

Recent advances in chemotherapy for pancreatic cancer: evidence from Japan and recommendations in guidelines
por: Okusaka, Takuji, et al.
Publicado: (2020)

New Era of Endoscopic Ultrasound-Guided Tissue Acquisition: Next-Generation Sequencing by Endoscopic Ultrasound-Guided Sampling for Pancreatic Cancer
por: Imaoka, Hiroshi, et al.
Publicado: (2019)

Chemotherapy for hepatocellular carcinoma: The present and the future
por: Le Grazie, Marco, et al.
Publicado: (2017)

Past exposure to hepatitis B virus as a risk factor for hepatocellular carcinoma in patients with chronic liver disease.
por: Okada, S., et al.
Publicado: (1998)

Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a phase III randomized trial
por: Ikeda, Masafumi, et al.
Publicado: (2017)

A Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetics of Napabucasin Combined with Sorafenib in Japanese Patients with Unresectable Hepatocellular Carcinoma
por: Okusaka, Takuji, et al.
Publicado: (2023)

Phase I study of tivantinib in Japanese patients with advanced hepatocellular carcinoma: Distinctive pharmacokinetic profiles from other solid tumors
por: Okusaka, Takuji, et al.
Publicado: (2015)

Neoadjuvant Chemotherapy and Targeted Therapy in Breast Cancer: Past, Present, and Future
por: Gampenrieder, Simon P., et al.
Publicado: (2013)

Past, Present, and Future of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer
por: Mishra, Mona, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_uqlolfunkd7cbnv26h2c0aa0i4